The literature for the complete document has been assessed, and all Chapters of the 2026 Penile Cancer Guidelines have been updated. New data have been included in the following Sections, resulting in new Sections, and new and revised guidelines:
- New text additions and references throughout Chapter 3.
- Incorporation of new text and references throughout Chapter 5, including a new Section 5.3 on genomic testing, as well as a new Figure 5.1 providing information on clinical cN0 management.
- New text additions and references throughout Chapter 6, with an updated summary of evidence in Section 6.1.5 on local treatment of penile carcinoma. A new figure is provided in Section 6.2: Figure 6.1, which provides information on regional lymph node management: clinically evident disease (cN1–cN3). Section 6.5.2.a on immunotherapy has also been restructured.
- A new figure in Section 6.5, Figure 6.2, provides information on systemic and palliative therapies for advanced disease.
- Substantial text additions have been made to Section 7, and the Section has been restructured, including the new Section 7.4.1 on the advantages of centralised care, Section 7.4.2 on Guidelines adherence, Section 7.4.3 on survival, and Section 7.4.4 on the disadvantages of centralised care.
- Updated summary of evidence and new guideline in Chapter 7 regarding follow-up and quality of life